Genelux (GNLX) Projected to Release Earnings on Wednesday

Key Points

• Genelux is expected to report Q3 2026 earnings before the market opens on November 4, with analysts forecasting a loss of $0.20 per share. Its earnings conference call is scheduled for November 13 at 4:00 p.m. ET.
• The company reported a $0.21-per-share loss in the prior quarter, missing estimates by $0.01. Analysts project full-year and next-year losses of $0.81 and $0.68 per share, respectively.
• Genelux shares opened at $2.05, near their one-year low of $1.86, while analyst views remain mixed but yield a “Moderate Buy” consensus and a $20 price target. Insiders sold 47,822 shares worth approximately $129,482 over the past 90 days.

Genelux (NASDAQ:GNLX - Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.20) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, analysts expect Genelux to post ($0.81) EPS for the current fiscal year and ($0.68) EPS for the next fiscal year.

Genelux Price Performance

Shares of NASDAQ GNLX opened at $2.05 on Wednesday. Genelux has a 1 year low of $1.86 and a 1 year high of $8.53. The firm has a 50-day simple moving average of $2.49 and a two-hundred day simple moving average of $2.70. The company has a market cap of $92.75 million, a P/E ratio of -2.38 and a beta of 0.59.

Analysts Set New Price Targets

A number of research analysts have recently commented on GNLX shares. Lucid Cap Mkts raised Genelux to a "strong-buy" rating in a research note on Wednesday, September 16th. Weiss Ratings reissued a "sell (e+)" rating on shares of Genelux in a research note on Thursday, October 15th. Benchmark reissued a "speculative buy" rating on shares of Genelux in a research note on Tuesday, August 18th. Finally, Wall Street Zen upgraded Genelux from a "strong sell" rating to a "sell" rating in a report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.00.

Insider Transactions at Genelux

In related news, insider Yong Yu sold 9,683 shares of the firm's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $2.75, for a total value of $26,628.25. Following the transaction, the insider owned 258,688 shares of the company's stock, valued at $711,392. This trade represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas Zindrick sold 34,463 shares of the firm's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total transaction of $92,016.21. Following the completion of the transaction, the chief executive officer directly owned 1,226,427 shares in the company, valued at $3,274,560.09. This represents a 2.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 47,822 shares of company stock worth $129,482. Company insiders own 7.50% of the company's stock.

Genelux Company Profile

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company's lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer.

Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.

Founded in 2001 and headquartered in San Diego, California, Genelux conducts its research and clinical development activities primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.